Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Neutral Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a research report report published on Friday, Marketbeat Ratings reports.

ZLDPF has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Four equities research analysts have rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock traded down $17.72 during trading hours on Friday, hitting $39.95. The stock had a trading volume of 83,428 shares, compared to its average volume of 822. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $101.29. The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of 2.92 and a beta of 0.75. The stock’s fifty day moving average is $64.22 and its two-hundred day moving average is $70.62. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.34) by $0.53. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. As a group, analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Trending Headlines about Zealand Pharma A/S

Here are the key news stories impacting Zealand Pharma A/S this week:

• Positive Sentiment: Roche and Zealand reported the midstage (Phase 2) trial met its prespecified goal and highlighted tolerability, saying the data support further development of petrelintide for chronic weight management (either alone or in combination). Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
• Positive Sentiment: Zealand’s own releases and coverage from business outlets framed the Phase 2 readout as positive for petrelintide, emphasizing potential to advance the program and the drug’s amylin-analog mechanism as a differentiated approach in weight management. Zealand Pharma announces positive Phase 2 results for petrelintide
• Positive Sentiment: Industry press also described the Roche/Zealand collaboration as achieving a successful midstage readout, supporting continued development of the program. Roche succeeds in mid-stage trial for obesity drug developed with Zealand
• Neutral Sentiment: William Blair reaffirmed a “market perform” rating on Zealand, leaving guidance unchanged — a sign analysts are holding a wait‑and‑see stance rather than turning bullish. (Current quoted price cited in analyst notes: $39.95.)
• Neutral Sentiment: Cantor Fitzgerald likewise reaffirmed a “neutral” rating, indicating no immediate upgrades from these sell‑side firms despite the trial news. (Current quoted price cited in analyst notes: $39.95.)
• Negative Sentiment: MarketWatch reported that the trial’s weight‑loss results were disappointing relative to market expectations, and that focus on the magnitude of weight loss (rather than tolerability or hit/miss of a specific statistical endpoint) spurred the selloff. Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
• Negative Sentiment: MSN summarized investor disappointment over the weight‑loss magnitude in the Phase 2 readout and noted the sharp share decline as traders punished the perceived shortfall versus expectations. This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.